Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new trial against the companies.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions. Three Motley Fool contr ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in ...

Two former Abbott Laboratories employees have sued the company ... She was tasked with creating new processes to prevent poor-quality products from leaving the facility. Mayhew was also on ...

The CE mark is an affirmation by a product's manufacturer that it conforms ... The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.